NEUP
Neuphoria Therapeutics Inc.
Price Chart
Latest Quote
$3.38
| Previous Close | $3.42 |
| Open | $3.39 |
| Day High | $3.46 |
| Day Low | $3.35 |
| Volume | 26,699 |
Stock Information
| Shares Outstanding | 5.41M |
| Total Debt | $34K |
| Cash Equivalents | $19.87M |
| Revenue | $1.17M |
| Net Income | $-13.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.34M |
| EPS (TTM) | $-3.06 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.54M |
| Sales | $1.17M |
| Income | $-13.45M |
| Book/sh | $4.55 |
| Cash/sh | $3.67 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 27.33 |
| Current Ratio | 27.85 |
| Debt/Eq | 0.14 |
Returns & Margins
| ROA | -19.66% |
| ROE | -61.70% |
| Gross Margin | 100.00% |
| Operating Margin | -15.66% |
Ownership
| Insider Ownership | 5.02% |
| Institutional Ownership | 42.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.38 |
| P/S | 15.62 |
| P/B | 0.75 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.40 |
| SMA50 | $3.62 |
| SMA200 | $4.18 |
| RSI | 47.89 |
| ATR | 0.1246 |
| Shares Float | 5.37M |
| Short Float | 0.45% |
| Short Ratio | 1.11 |
| Rel Volume | 0.16 |
Performance History
| Week | +0.00% |
| Month | -7.12% |
| Quarter | -10.79% |
| 6 Months | -33.79% |
| YTD | -11.26% |
| Year | -45.67% |
| 3 Years | -92.59% |
| 10 Years | -98.08% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $3.39 | 3,638 |
| 2026-10-26 | $3.38 | 26,700 |
| 2026-10-23 | $3.44 | 73,000 |
| 2026-10-22 | $3.48 | 4,800 |
| 2026-10-21 | $3.48 | 8,800 |
| 2026-10-20 | $3.39 | 20,800 |
| 2026-10-19 | $3.31 | 39,500 |
| 2026-10-16 | $3.30 | 76,000 |
| 2026-10-15 | $3.31 | 18,700 |
| 2026-10-14 | $3.24 | 44,100 |
| 2026-10-13 | $3.39 | 26,600 |
| 2026-10-12 | $3.32 | 10,000 |
| 2026-10-09 | $3.36 | 2,500 |
| 2026-10-08 | $3.35 | 16,500 |
| 2026-10-07 | $3.42 | 4,500 |
| 2026-10-06 | $3.45 | 16,500 |
| 2026-10-05 | $3.45 | 15,500 |
| 2026-10-02 | $3.47 | 12,600 |
| 2026-10-01 | $3.51 | 14,300 |
| 2026-09-30 | $3.56 | 10,400 |
| 2026-09-29 | $3.57 | 15,000 |
| 2026-09-28 | $3.65 | 2,900 |
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
đ° Latest News
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $1,174,165 | - | $0 | $0 |
| Operating Revenue | $1,174,165 | - | $0 | $0 |
| Expenses | ||||
| Total Expenses | $10,183,741 | - | $17,797,161 | $21,560,234 |
| Other Income Expense | $-5,247,099 | - | $1,997,578 | $-283,775 |
| Net Non Operating Interest Income Expense | $665,571 | - | $220,097 | $323,158 |
| Operating Expense | $10,183,741 | - | $17,797,161 | $21,560,234 |
| Other Operating Expenses | $-800,904 | - | $-95,215 | $-422,742 |
| General And Administrative Expense | $7,439,224 | - | $8,474,591 | $8,911,271 |
| Interest Expense | - | - | - | $14,085 |
| Rent Expense Supplemental | - | - | - | $145,853 |
| Total Other Finance Cost | - | - | - | $5,264 |
| Interest Expense Non Operating | - | - | - | $14,085 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Net Interest Income | $665,571 | - | $220,097 | $323,158 |
| Interest Income | $665,571 | - | $220,097 | $323,158 |
| Normalized Income | $-8,257,303 | $-239,149 | $-17,477,759 | $-21,099,605 |
| Net Income From Continuing And Discontinued Operation | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Total Operating Income As Reported | $-16,451,066 | - | $-17,892,376 | $-21,982,976 |
| Net Income Common Stockholders | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Net Income | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Net Income Including Noncontrolling Interests | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Net Income Continuous Operations | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Pretax Income | $-13,591,104 | - | $-15,579,486 | $-21,520,851 |
| Special Income Charges | $-6,640,586 | $0 | - | $-654,107 |
| Interest Income Non Operating | $665,571 | - | $220,097 | $323,158 |
| Operating Income | $-9,009,576 | - | $-17,797,161 | $-21,560,234 |
| Net Income Discontinuous Operations | - | - | - | - |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Amortization Of Intangibles Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | - | $-0.23 | $-18.62 | $-0.16 |
| Basic EPS | - | $-0.23 | $-18.62 | $-0.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $-52,471 | $-44,827 | $11,985 | $-1,703 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,099,522 | - | $-19,131,748 | $-20,613,267 |
| Total Unusual Items | $-5,247,099 | - | $1,997,578 | $-283,775 |
| Total Unusual Items Excluding Goodwill | $-5,247,099 | - | $1,997,578 | $-283,775 |
| Reconciled Depreciation | $662,955 | - | $662,991 | $663,192 |
| EBITDA (Bullshit earnings) | $-8,346,621 | - | $-17,134,170 | $-20,897,042 |
| EBIT | $-9,009,576 | - | $-17,797,161 | $-21,560,234 |
| Diluted NI Availto Com Stockholders | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Tax Provision | $-139,173 | - | $-87,320 | $-139,174 |
| Impairment Of Capital Assets | $5,409,608 | $0 | - | - |
| Restructuring And Mergern Acquisition | $1,230,978 | $0 | - | $654,107 |
| Gain On Sale Of Security | $1,393,487 | - | $1,997,578 | $-283,775 |
| Research And Development | $3,545,421 | - | $9,417,785 | $13,071,705 |
| Selling General And Administration | $7,439,224 | - | - | $8,911,271 |
| Other Gand A | $7,439,224 | - | $8,474,591 | $8,911,271 |
| Diluted Average Shares | - | $1,622,924 | $832,225 | $122,394,618 |
| Basic Average Shares | - | $1,622,924 | $832,225 | $122,394,618 |
| Gain On Sale Of Ppe | - | - | - | $0 |
| Rent And Landing Fees | - | - | - | $145,853 |
| Amortization | - | - | - | - |
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $16,959,740 | $3,332,832 | $7,186,124 | $23,530,941 |
| Total Assets | $28,709,016 | $27,649,093 | $28,562,948 | $44,927,475 |
| Total Non Current Assets | $7,640,282 | $14,455,335 | $15,236,336 | $16,165,818 |
| Goodwill And Other Intangible Assets | $7,640,282 | $14,157,540 | $14,824,439 | $15,619,941 |
| Other Intangible Assets | $4,142,060 | $5,467,522 | $6,130,253 | $6,767,840 |
| Current Assets | $21,068,734 | $13,193,758 | $13,326,612 | $28,761,657 |
| Restricted Cash | $0 | - | - | $0 |
| Prepaid Assets | $389,772 | $458,765 | $797,478 | $1,005,089 |
| Receivables | $813,431 | $126,884 | $426,087 | $4,666,991 |
| Other Receivables | $810,778 | $96,154 | $416,072 | $4,651,941 |
| Taxes Receivable | $2,653 | $30,444 | $9,758 | $15,049 |
| Accrued Interest Receivable | $0 | $286 | $257 | - |
| Cash Cash Equivalents And Short Term Investments | $19,865,531 | $12,608,109 | $12,103,047 | $23,089,577 |
| Cash And Cash Equivalents | $19,865,531 | $12,608,109 | $12,103,047 | $23,089,577 |
| Other Non Current Assets | - | $78,826 | $78,897 | $81,861 |
| Cash Financial | - | - | $18,250,255 | $23,089,577 |
| Non Current Prepaid Assets | - | - | - | - |
| Other Current Assets | - | - | - | - |
| Accounts Receivable | - | - | - | - |
| Gross Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $34,345 | $272,738 | $386,915 | $477,150 |
| Current Debt And Capital Lease Obligation | $34,345 | $155,110 | $147,080 | $110,093 |
| Current Debt | $34,345 | $33,120 | $33,150 | - |
| Other Current Borrowings | $34,345 | $33,120 | $33,150 | - |
| Long Term Debt And Capital Lease Obligation | - | $117,628 | $239,835 | $367,057 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,108,994 | $10,158,721 | $6,552,385 | $5,776,593 |
| Total Non Current Liabilities Net Minority Interest | $3,352,413 | $6,329,648 | $3,813,597 | $3,468,217 |
| Other Non Current Liabilities | $1,025,301 | $590,648 | $2,471,049 | $1,856,674 |
| Derivative Product Liabilities | $1,971,172 | $4,657,832 | $0 | - |
| Non Current Deferred Liabilities | $355,940 | $963,540 | $1,102,713 | $1,237,291 |
| Non Current Deferred Taxes Liabilities | $355,940 | $963,540 | $1,102,713 | $1,237,291 |
| Current Liabilities | $756,581 | $3,829,073 | $2,738,788 | $2,308,376 |
| Other Current Liabilities | $53,165 | $37,581 | $39,405 | - |
| Payables And Accrued Expenses | $669,071 | $3,636,382 | $2,552,303 | $1,916,708 |
| Payables | $385,584 | $2,243,662 | $1,439,291 | $1,070,993 |
| Accounts Payable | $385,584 | $2,243,662 | $1,439,291 | $1,070,993 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $24,600,022 | $17,490,372 | $22,010,563 | $39,150,882 |
| Total Equity Gross Minority Interest | $24,600,022 | $17,490,372 | $22,010,563 | $39,150,882 |
| Stockholders Equity | $24,600,022 | $17,490,372 | $22,010,563 | $39,150,882 |
| Gains Losses Not Affecting Retained Earnings | $-2,063,170 | $-3,013,595 | $-3,058,783 | $8,615,100 |
| Other Equity Adjustments | $-2,063,170 | $-3,013,595 | $-3,058,783 | - |
| Retained Earnings | $-191,798,634 | $-177,977,071 | $-162,484,905 | $-119,219,156 |
| Other | ||||
| Ordinary Shares Number | $5,411,334 | $198,711,663 | $1,468,735,424 | $1,353,350,744 |
| Share Issued | $5,411,334 | $198,711,663 | $1,468,735,424 | $1,353,350,744 |
| Tangible Book Value | $16,959,740 | $3,332,832 | $7,186,124 | $23,530,941 |
| Invested Capital | $24,634,367 | $17,523,492 | $22,043,713 | $39,150,882 |
| Working Capital | $20,312,153 | $9,364,685 | $10,587,824 | $26,453,281 |
| Capital Lease Obligations | $0 | $239,618 | $353,765 | $477,150 |
| Total Capitalization | $24,600,022 | $17,490,372 | $22,010,563 | $39,150,882 |
| Additional Paid In Capital | $218,461,772 | $198,481,027 | $187,554,251 | - |
| Capital Stock | $54 | $11 | $0 | $149,754,939 |
| Common Stock | $54 | $11 | $0 | $149,754,939 |
| Current Capital Lease Obligation | $0 | $121,990 | $113,930 | $110,093 |
| Current Accrued Expenses | $283,487 | $1,392,720 | $1,113,012 | $845,715 |
| Goodwill | $3,498,222 | $8,690,018 | $8,694,186 | $8,852,101 |
| Net PPE | $0 | $218,969 | $333,000 | $464,015 |
| Gross PPE | $0 | $218,969 | $378,237 | $637,372 |
| Long Term Capital Lease Obligation | - | $117,628 | $239,835 | $367,057 |
| Accumulated Depreciation | - | $-45,722 | $-45,237 | $-173,357 |
| Other Properties | - | $218,969 | $330,478 | - |
| Machinery Furniture Equipment | - | $47,716 | $47,759 | $49,554 |
| Employee Benefits | - | - | $22,398 | $7,196 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $457,017 | $281,575 |
| Leases | - | - | $854,500 | $587,819 |
| Properties | - | - | $0 | $0 |
| Foreign Currency Translation Adjustments | - | - | - | - |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | - |
| Investments And Advances | - | - | - | - |
| Other Investments | - | - | - | - |
| Other Short Term Investments | - | - | - | - |
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,353,074 | - | $-14,680,777 | $-14,637,720 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,353,074 | - | $-14,680,777 | $-14,637,720 |
| Cash Flow From Continuing Operating Activities | $-12,353,074 | - | $-14,680,777 | $-14,637,719 |
| Operating Gains Losses | $-1,127,008 | - | $-366,333 | $-556,782 |
| Cash Flowsfromusedin Operating Activities Direct | - | - | - | - |
| Classesof Cash Receiptsfrom Operating Activities | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | - | - | $317,415 |
| Cash Flow From Continuing Investing Activities | - | - | - | $317,415 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $17,915,883 | - | $10,111,979 | $3,858,451 |
| Financing Cash Flow | $17,915,883 | - | $15,108,794 | $3,858,451 |
| Cash Flow From Continuing Financing Activities | $17,915,883 | - | $15,108,794 | $3,858,451 |
| Net Common Stock Issuance | $17,915,883 | - | $10,111,979 | $3,858,451 |
| Common Stock Issuance | $17,915,883 | - | $10,111,979 | $3,858,451 |
| Net Other Financing Charges | - | - | - | $-1,126,827 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $3,857 | - | - | - |
| End Cash Position | $19,865,531 | - | $12,686,935 | $12,181,944 |
| Beginning Cash Position | $14,288,690 | - | $12,181,944 | $23,205,035 |
| Effect Of Exchange Rate Changes | $14,032 | - | $76,974 | $-243,822 |
| Changes In Cash | $5,562,809 | - | $428,017 | $-10,779,269 |
| Change In Working Capital | $-4,054,414 | $-496,826 | $1,454,857 | $4,584,489 |
| Change In Other Working Capital | $-139,173 | $-601,507 | $-139,173 | $-139,173 |
| Change In Other Current Liabilities | $-116,314 | - | $-126,111 | $-99,767 |
| Change In Payables And Accrued Expense | $-3,347,865 | - | $1,082,225 | $512,255 |
| Change In Accrued Expense | $-2,579,080 | - | $277,854 | $138,079 |
| Change In Payable | $-768,785 | - | $804,371 | $374,176 |
| Change In Account Payable | $-768,785 | - | $804,371 | $374,176 |
| Change In Prepaid Assets | $350,421 | - | $338,713 | $173,975 |
| Change In Receivables | $-801,483 | - | $299,203 | $4,137,199 |
| Changes In Account Receivables | $-801,483 | - | $299,203 | $4,137,199 |
| Other Non Cash Items | $-96,276 | $831,017 | $-1,754,934 | $707,749 |
| Stock Based Compensation | $351,600 | - | $814,808 | $1,345,309 |
| Asset Impairment Charge | $5,362,000 | $0 | - | - |
| Depreciation Amortization Depletion | $662,955 | - | $662,991 | $663,192 |
| Depreciation And Amortization | $662,955 | - | $662,991 | $663,192 |
| Gain Loss On Investment Securities | $-1,730,321 | - | $-338,983 | - |
| Net Foreign Currency Exchange Gain Loss | $603,313 | - | $-27,350 | $-556,782 |
| Net Income From Continuing Operations | $-13,451,931 | - | $-15,492,166 | $-21,381,677 |
| Proceeds From Stock Option Exercised | - | - | $4,996,815 | $0 |
| Repayment Of Debt | - | - | - | $-105,936 |
| Net Issuance Payments Of Debt | - | - | - | $-105,936 |
| Net Long Term Debt Issuance | - | - | - | $-105,936 |
| Long Term Debt Payments | - | - | - | $-105,936 |
| Interest Received Cfi | - | - | - | $317,415 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Change In Other Current Assets | - | - | - | $170,945 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Change In Inventory | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
| Common Stock Payments | - | - | - | - |
| Interest Paid Direct | - | - | - | - |
| Classesof Cash Payments | - | - | - | - |
| Paymentsto Suppliersfor Goodsand Services | - | - | - | - |
| Receiptsfrom Government Grants | - | - | - | - |
| Receiptsfrom Customers | - | - | - | - |